Triazole Resistance in *Aspergillus fumigatus* Clinical Isolates Obtained in Nanjing, China

Ming Zhang¹, Chun-Lai Feng², Fei Chen¹, Qian He¹, Xin Su¹, Yi Shi¹

¹Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China
²Department of Respiratory Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, China

**Abstract**

**Background:** During the past decades, the incidence of invasive aspergillosis (IA) caused by *Aspergillus fumigatus* has increased dramatically. The aims of this study were to investigate the susceptibility of clinical isolates of *A. fumigatus* to triazole and the underlying cyp51A mutations in triazole-resistant *A. fumigatus*. 

**Methods:** A total of 126 *A. fumigatus* clinical isolates from 126 patients with proven or probable IA were obtained from four large tertiary hospitals in Nanjing, China, between August 2012 and July 2015. The determination of minimal inhibitory concentrations (MICs) for itraconazole, voriconazole, and posaconazole was performed by broth microdilution according to the European Committee on Antimicrobial Susceptibility Testing reference method.

**Results:** A total of 4 *A. fumigatus* isolates (3.17%) were confirmed to be itraconazole resistant, with MICs of ≥8 mg/L, and one isolate (0.8%) was confirmed to be voriconazole resistant and posaconazole resistant, with MICs of 4 mg/L and 0.5 mg/L, respectively. We found that two of the 4 isolates of triazole-resistant *A. fumigatus* had the L98H amino acid substitution in combination with a 34-base pair tandem repeat in the promoter region, one isolate had an M220I mutation, and another itraconazole-resistant isolate did not have a substitution in the cyp51A gene.

**Conclusions:** This study shows that triazole-resistant *A. fumigatus* clinical isolates are present in Nanjing, China, which is a new challenge to the clinical management of IA.

**Key words:** *Aspergillus fumigatus*; cyp51A; Minimal Inhibitory Concentrations; TR34/L98H; Triazole Resistance

**Introduction**

Invasive aspergillosis (IA) is a life-threatening infection in immunocompromised patients associated with severe mortality. *Aspergillus fumigatus* is the most common species recovered from cases of IA (90% of IA cases involving the lungs).¹,² Triazole antifungals, such as itraconazole, posaconazole, and voriconazole, are first-line drugs in prophylaxis and treatment of IA.³ However, during the past decades, a number of clinical failures of IA management due to triazole-resistant *A. fumigatus* have been reported,⁴ which brings new challenges to the clinical treatment of IA.

A global survey in the year 2005 showed that there was no itraconazole-resistant *A. fumigatus* in the 331 isolates that were examined.⁹ However, in the year 2009, 43 strains of *A. fumigatus* from a total of 637 (6.75%) isolates were determined to have an itraconazole minimum inhibitory concentrations (MICs) of ≥2 mg/L.¹⁰ The major mechanism of triazole resistance in *A. fumigatus* involves mutations in the cyp51A gene encoding 14α-demethylase. Some specific point mutations, such as G54, M220, I266, S297, and L98H amino acid substitution in combination with a 34-base pair tandem repeat (TR) in the promoter region, have been identified as causes of triazole resistance.¹¹⁻¹⁴ TR/L98H, considered as an intrinsic resistance mechanism, has been identified mainly in Netherlands and China.⁸⁻¹⁵ At present, a few studies have focused on the prevalence of triazole resistance among *A. fumigatus* clinical isolates

**Address for correspondence:** Dr. Yi Shi, Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China
E-Mail: shiyi56@126.com

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

© 2017 Chinese Medical Journal | Produced by Wolters Kluwer - Medknow

**Access this article online**

Quick Response Code:  
Website: www.cmj.org  
DOI: 10.4103/0366-6999.201609

**Received:** 02-12-2016 **Edited by:** Qiang Shi  
**How to cite this article:** Zhang M, Feng CL, Chen F, He Q, Su X, Shi Y. Triazole Resistance in *Aspergillus fumigatus* Clinical Isolates Obtained in Nanjing, China. Chin Med J 2017;130:665-8.
in vitro triazole susceptibilities of a large collection of \textit{A. fumigatus} clinical isolates and analyzed \textit{cyp51A} mutations in the triazole-resistant \textit{A. fumigatus}.

**Methods**

**Isolates**

\textit{A. fumigatus} clinical isolates were obtained from four tertiary hospitals (Jinling Hospital, Medical School of Nanjing University; Drum Tower Hospital, Medical School of Nanjing University; the First Affiliate Hospital of Nanjing Medical University; and Zhongda Hospital, Southeast University) in Nanjing, China, between August 2012 and July 2015. All isolates were identified as \textit{A. fumigatus} by macroscopic and micromorphological characteristics, thermotolerance at 48°C, and molecular identification. Conidia were stored in 10% glycerol broth at −80°C. The strains of \textit{A. fumigatus} American Type Culture Collection 204305 were included as quality controls.

**Antifungal agents**

Itraconazole (Janssen Pharmaceutica NV, Turnhout, Turnhoutseweg, Belgium), voriconazole (Pfizer Inc., Dun Laoghaire, Ireland), and posaconazole (Merck Sharp & Dohme Pty. Ltd., New South Wales, Australia) were provided in powder form. Itraconazole, voriconazole, and posaconazole were dissolved in 100% dimethyl sulfoxide in powder form. Itraconazole, voriconazole, and posaconazole were dissolved in 100% dimethyl sulfoxide and stored at −80°C.

**Susceptibility testing**

The \textit{in vitro} antifungal susceptibility testing was performed by broth microdilution according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference method.\(^{11}\) Itraconazole, voriconazole, and posaconazole were diluted to the required concentrations in RPMI with 2% of glucose stock solutions. Spore suspensions were prepared to a final working inoculum of 2–5 × 10\(^5\) CFU/mL. Microdilution plates were incubated at 35°C for 48 h. The endpoints for MICs were defined as the lowest drug concentration that caused complete growth inhibition.

The EUCAST clinical breakpoints were used,\(^{17,18}\) MICs >2 mg/L for itraconazole and voriconazole and >0.25 mg/L for posaconazole were considered resistant; MICs ≤1 mg/L for itraconazole and voriconazole and ≤0.125 mg/L for posaconazole were considered susceptible.

**Sequence analysis**

For resistant isolates, the entire \textit{cyp51A} gene and its promoter were amplified as previously described,\(^{13}\) The forward primer 5’-ATGGTGCGATGGCTATGG-3’ and reverse primer 5’-AGTTTCAAGGACTCCTTTTC-3’ were used in polymerase chain reaction amplification. Sequence analysis was determined on an ABI 3730XL DNA sequencer (Applied Biosystems, Inc., Foster City, USA). Sequences were compared to a wild type \textit{A. fumigatus} strain (GenBank Accession No. AF. 338659).

**Results**

Over a period of 4 years from August 2012 to July 2015, a total of 126 \textit{A. fumigatus} clinical isolates from 126 patients with proven or probable IA were collected and analyzed. All the isolates were confirmed as \textit{A. fumigatus sensu stricto}. Figure 1 shows the distribution of MIC values for itraconazole, voriconazole, and posaconazole according to the EUCAST broth microdilution procedure. The results for the quality control strains were in the acceptable range. A total of 4 \textit{A. fumigatus} isolates (3.17%) were confirmed to be itraconazole resistant with MICs of ≥8 mg/L, and one isolate (0.8%) was confirmed to be voriconazole resistant and posaconazole resistant, with MICs of 4 mg/L and 0.5 mg/L, respectively.

The MIC values, \textit{cyp51A} substitutions, and characteristics of triazole-resistant isolates of \textit{A. fumigatus} are shown in Table 1. Two of the four isolates were demonstrated to contain the TR34/L98H substitution. One isolate from a chronic obstructive pulmonary disease (COPD) patient underwent itraconazole therapy had the M220I mutation. Moreover, another itraconazole-resistant isolate did not have a substitution in the \textit{cyp51A} gene.

**Discussion**

In this study, we investigated the prevalence of triazole resistance and examined \textit{cyp51A} mutations among \textit{A. fumigatus} clinical isolates from patients with proven or probable IA in Nanjing, China. The percentage of triazole-resistant \textit{A. fumigatus} isolates was 3.17% (4/126). This rate is similar to that reported in Germany (3.2%)\(^{14}\) but lower than data from some previous studies: from a total of 497 \textit{A. fumigatus} isolates, in a worldwide survey from 62 medical centers, 5.8% showed triazole resistance,\(^{12}\) and similarly, a rate of 5.3% was shown in a nationwide multicenter study from Netherlands\(^{15}\) and 5.5% in Copenhagen, Denmark.\(^{19}\) Astonishingly, a rate of 14% and 20% of \textit{A. fumigatus} clinical isolates were noted as having triazole antifungal resistance in the year 2008 and 2009, respectively, in Manchester.\(^{20}\) Nevertheless, the prevalence rate in the present study is higher compared to Spain (2.5%)\(^{21}\) and India (1.7%).\(^{22}\)

![Figure 1](image-url)
Mutations in the cyp51A gene encoding 14α-demethylase were the major mechanisms of triazole resistance in A. fumigatus. In the present study, two triazole-resistant isolates harbored the TR34/L98H mutation and one M220l mutation. Some studies suggested that the TR/L98H mutation acquired in the environment due to azole fungicides usage in agriculture.[23,24] We found that one itraconazole-resistant isolate harbored the TR34/L98H mutation was cross-resistance to both voriconazole and posaconazole. Similarly, multiazole-resistant isolates with TR34/L98H mutations were detected in Asia as well as in Europe.[12,14] In this study, the itraconazole-resistant isolate with the M220l mutation was considered as acquired resistance as a result of prolonged treatment with itraconazole. Other specific point mutations, such as G54, I266, and S297, have been identified as primary causes of triazole-acquired resistance.[11-14] However, in this study, one itraconazole-resistant isolate was without substitution in the cyp51A gene. Tashiro et al.[11] showed that 43% of triazole-resistant isolates did not contain a substitution in the cyp51A gene. Therefore, cyp51A gene mutation is not the only mechanism of triazole resistance in A. fumigatus. Other possible mechanisms (e.g., HapE mutation, efflux pumps, cholesterol import by A. fumigatus) might contribute to triazole resistance.[15]

There are a series of limitations in this study. We only investigated A. fumigatus clinical isolates from patients with proven or probable IA in four hospitals in Nanjing; therefore, the results might not be representative. The epidemiological data on the resistance of triazole to A. fumigatus were still insufficient, and the mechanisms of triazole resistance have not been fully investigated.

In conclusion, this study confirmed the occurrence of triazole-resistant A. fumigatus clinical isolates, with a 3.17% resistance rate in Nanjing, China. Triazole-resistant A. fumigatus might develop through different mechanisms, which brings new challenges to the clinical treatment of IA. Larger studies are needed to better investigate triazole-resistant A. fumigatus in different regions of China and elucidate the underlying mechanisms of triazole resistance.

**Acknowledgments**

We are very grateful to Ya-Ning Mei from the First Affiliate Hospital of Nanjing Medical University, Zhi-Feng Zhang from the Drum Tower Hospital, Medical School of Nanjing University, Hai-Yan Xi from the Jinling Hospital, Medical School of Nanjing University, and Jian-Ming Chen from the Zhongda Hospital, Southeast University, who provided samples. We would like to thank the entire staff of the Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University.

**References**

1. Perfect JR, Cox GM, Lee JY, Kaufman CA, de Repentigny L, Chapman SW, et al. The impact of culture isolation of *Aspergillus* species: A hospital-based survey of aspergillosis. Clin Infect Dis 2001;33:1824-33. doi: 10.1086/323900.

2. Shi YQ, Li P, Wu T, Ding Y, Shi Y, Wylam ME, et al. Integrated therapy for invasive pulmonary aspergillosis in a patient with asthma and chronic obstructive pulmonary disease overlap syndrome. Chin Med J 2015;128:2265-6. doi: 10.4103/0366-6999.162511.

3. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60. doi: 10.1086/525258.

4. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, et al. Itraconazole resistance in *Aspergillus fumigatus*. Antimicrob Agents Chemother 1997;41:1364-8.

5. Dannaoui E, Borel E, Monier MF, Piens MA, Picot S, Persat F. Acquired itraconazole resistance in *Aspergillus fumigatus*. J Antimicrob Chemother 2001;47:333-40. doi: 10.1093/jac/47.3.333.

6. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, et al. Frequency and evolution of azole resistance in *Aspergillus fumigatus* associated with treatment failure. Emerg Infect Dis 2009;15:1068-76. doi: 10.3201/eid1507.090043.

7. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, et al. Multi-azole resistance in *Aspergillus fumigatus*. Int J Antimicrob Agents 2006;28:450-3. doi: 10.1016/j.ijantimicag.2006.08.017.

8. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in *Aspergillus fumigatus*: A side-effect of environmental fungicide use? Lancet Infect Dis 2009;9:789-95. doi: 10.1016/S1473-3099(09)70265-8.

9. Pfaffer MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of clinical isolates of *Candida* species, *Cryptococcus neoformans*, and *Aspergillus* species to itraconazole: Global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 2005;43:3807-10. doi: 10.1128/JCM.43.8.3807-3810.2005.

10. Pfaffer MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, et al. Wild-type MIC distribution and epidemiological cutoff

---

**Table 1: Characteristics of triazole-resistant isolates of *Aspergillus fumigatus***

| Isolates number | Patient age (years)/sex | Underlying condition | Disease | Prior azole treatment | Antifungal treatment | Outcome | MIC (mg/L) | Mutation(s) in cyp51A gene |
|-----------------|------------------------|----------------------|---------|-----------------------|---------------------|---------|------------|--------------------------|
| AF.28           | 56/male                | COPD                 | IPA     | ITZ                   | ITZ                 | Died    | >8.00      | 0.50, 0.25                | M220l                    |
| AF.44           | 48/female              | SLE                  | IPA     | None                  | ITZ and CAS         | Died    | >8.00      | 4.00, 0.50                | TR/L98H                  |
| AF.98           | 63/female              | NHL, BMD             | IPA     | None                  | VRZ and CAS         | Cure    | >8.00      | 2.00, 0.25                | TR/L98H                  |
| AF.118          | 65/male                | DM                   | IPA     | None                  | VRZ and CAS         | Cure    | >8.00      | 2.00, 0.25                | WT                       |

COPD: Chronic obstructive pulmonary disease; SLE: Systemic lupus erythematosus; NHL: Non-Hodgkin lymphoma; BMD: Bone marrow depression; DM: Diabetes mellitus; IPA: Invasive pulmonary aspergillosis; CAS: Caspofungin; MIC: Minimal inhibitory concentration; ITZ: Itraconazole; VRZ: Voriconazole; PSZ: Posaconazole; TR: Tandem repeat; WT: Wild type.
values for *Aspergillus fumigatus* and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2009;47:3142-6. doi: 10.1128/JCM.00940-09.

11. Tashiro M, Izumikawa K, Minematsu A, Hirano K, Iwanaga N, Ide S, *et al.* Antifungal susceptibilities of *Aspergillus fumigatus* clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother 2012;56:584-7. doi: 10.1128/AAC.05394-11.

12. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in *Aspergillus fumigatus* isolates from the ARTEMIS global surveillance study is primarily due to the TR/I98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011;55:4465-8. doi: 10.1128/AAC.00185-11.

13. Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJ. Azole resistance profile of amino acid changes in *Aspergillus fumigatus* CYP51A based on protein homology modeling. Antimicrob Agents Chemother 2010;54:2425-30. doi: 10.1128/AAC.01599-09.

14. Bader O, Weig M, Reichard U, Lugert R, Kuhns M, Christner M, *et al.* cyp51A-based mechanisms of *Aspergillus fumigatus* azole drug resistance present in clinical samples from Germany. Antimicrob Agents Chemother 2013;57:3513-7. doi: 10.1128/AAC.00167-13.

15. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, *et al.* Clinical implications of azole resistance in *Aspergillus fumigatus*, the Netherlands, 2007-2009. Emerg Infect Dis 2011;17:1846-54. doi: 10.3201/eid1710.110226.

16. Rodriguez-Tudela J, Donnelly J, Arendrup M, Arikan S, Barchiesi F, Bille J, *et al.* EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008;14:982-4. doi: 10.1111/j.1469-0691.2008.02086.x.

17. Hope WW, Cuenca-Estrella M, Lass-Flörl C, Arendrup MC; European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on voriconazole and *Aspergillus* spp. Clin Microbiol Infect 2013;19:E278-80. doi: 10.1111/1469-0691.12148.

18. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW; European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on *Aspergillus* and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect 2012;18:E248-50. doi: 10.1111/j.1469-0691.2012.03890.x.

19. Mortensen KL, Jensen RH, Johansen HK, Skov M, Pressler T, Howard SJ, *et al.* *Aspergillus* species and other molds in respiratory samples from patients with cystic fibrosis: A laboratory-based study with focus on *Aspergillus fumigatus* azole resistance. J Clin Microbiol 2011;49:2243-51. doi: 10.1128/JCM.00213-11.

20. Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P, *et al.* Azole antifungal resistance in *Aspergillus fumigatus*: 2008 and 2009. J Antimicrob Chemother 2010;65:2116-8. doi: 10.1093/jac/dkq279.

21. Escribano P, Peláez T, Muñoz P, Bouza E, Guinea J. Is azole resistance in *Aspergillus fumigatus* a problem in Spain? Antimicrob Agents Chemother 2013;57:2815-20. doi: 10.1128/AAC.02487-12.

22. Chowdhary A, Sharma C, Kathuria S, Hagen F, Meis JF. Prevalence and mechanism of triazole resistance in *Aspergillus fumigatus* in a referral chest hospital in Delhi, India and an update of the situation in Asia. Front Microbiol 2015;6:373-92. doi: 10.3389/fmicb.2015.00428.

23. Denning DW, Perlin DS. Azole resistance in *Aspergillus*: A growing public health menace. Future Microbiol 2011;6:1229-32. doi: 10.2217/fmb.11.118.

24. Snelders E, Camps SM, Karawajczyk A, Schaftenaar G, Kema GH, Lee HA, *et al.* Triazole fungicides can induce cross-resistance to medical triazoles in *Aspergillus fumigatus*. Plos One 2012;7:e31801-10. doi: 10.1371/journal.pone.0031801.

25. Chowdhary A, Sharma C, Hagen F, Meis JF. Exploring azole antifungal drug resistance in *Aspergillus fumigatus* with special reference to resistance mechanisms. Future Microbiol 2014;9:697-711. doi: 10.2217/fmb.14.27.